Grifols SA ADR (GRFS) is a prominent global healthcare company based in Barcelona, Spain, with a history dating back 100+ years, focused on developing life-saving therapies for patients with rare and chronic diseases. Grifols has a vast portfolio that primarily focuses on the Hematology and Hemotherapy sectors and offers products and services to over 100 countries worldwide.
The company's business is organized into four main divisions: Bioscience, Diagnostic, Hospital, and Bio Supplies. The Bioscience division specializes in the research, development, production, and commercialization of plasma derivatives. The Diagnostic division focuses on providing tools, information, and services to assist healthcare professionals with diagnostic testing. The Hospital division develops and implements intravenous solutions, clinical nutrition products, and medical devices. Lastly, the bio supplies business provides biological products for non-therapeutic use.
Grifols' dedication to innovation and improvement of health and well-being makes it a leader in plasma collection, with a network of more than 300 plasma donation centers in the U.S. Grifols, a pioneer in the plasmapheresis industry, is also one of the top producers of plasma-derived medicines globally.
The company has shown a deep commitment to improving patient care, contributing to scientific and technological research, and engaging in collaborations with hospitals, universities, and research centers throughout the world. An ethical and transparent approach defines Grifols, boasting first-class standard practices in sustainability and corporate responsibility that reflect in maintaining relationships with stakeholders, including employees, customers, patients, and investors.
Grifols SA ADR (GRFS) is publicly traded on the Nasdaq Global Select Market and the Madrid Stock Exchange. The American Depositary Receipt (ADR) program allows U.S. investors to buy shares in foreign companies without the need for cross-border transactions. Each ADR represents one Class B share of Grifols, S.A.
Despite various challenges, including economic uncertainties and the impact of the global pandemic, Grifols has displayed resilience. The company continually invests in strengthening global operations and expanding its product portfolio. This focus on expansion and product diversification proves Grifols' commitment to invest and grow, solidifying its place as a prominent player in the healthcare sector.
Income statement
Balance sheet statement
Cash flow statement
Current assets / Current liabilities
Equity / Debt / Cash
Dividends
Zacks Research has downgraded Grifols (NASDAQ:GRFS) from a "hold" to a "strong sell" rating. Other firms, including Wall Street Zen and JPMorgan Chase & Co., have also issued "hold" or "sell" ratings and decreased price targets for the biotechnology company. Institutional investors have adjusted their positions in Grifols, with several increasing their holdings during recent quarters.
Grifols, S.A. (NASDAQ:GRFS) experienced a 105% increase in short interest during September, reaching 7.0 million shares by the end of the month, representing 1.0% of shares outstanding. Despite institutional investors generally increasing their positions, analyst sentiment remains cautious with a "Reduce" consensus rating and a $10.00 average price target, as the stock opened at $7.17, near its 52-week low.
Wall Street Zen has downgraded Grifols (NASDAQ:GRFS) from a "Buy" to a "Hold" rating, aligning with a broader analyst consensus of "Reduce" and an average price target of $10.00. Despite the downgrade, several institutional investors, including Quantinno Capital Management and Flat Footed LLC, have recently increased their holdings in Grifols. The stock opened at $7.46, close to its moving averages, with a market capitalization of $5.08 billion.
Wall Street Zen has upgraded Grifols (NASDAQ:GRFS) from a "hold" to a "buy" rating, despite a broader analyst consensus of "Reduce." The company's shares opened at $7.31, close to its 52-week low, with a market capitalization of $4.98 billion. Several institutional investors, including Tidal Investments and Hennion & Walsh Asset Management, have recently increased their holdings in Grifols.
Grifols, S.A. (GRFS), a healthcare company specializing in plasma-derived medicines, shows a potential upside of 43.91% despite a slight revenue contraction. The stock is trading below its 50-day and 200-day moving averages, presenting a potential buying opportunity with an attractive forward P/E of 5.23 and a 3.73% dividend yield. Analysts show cautious optimism, with target prices suggesting significant upward movement, highlighting the company's strong product pipeline and strategic initiatives.